Triple-negative breast cancer has long been regarded as one of the most difficult forms of breast cancer to treat. Unlike tumors that carry estrogen, progesterone, or HER2 receptors, TNBC lacks the three molecular markers routinely used to guide targeted therapies. As a result, chemotherapy remains central to treatment, even though resistance and rapid disease progression are common. Now, a study published in the Journal of Molecular Medicine has identified an unexpected biological accomplice in TNBC: the sympathetic adrenergic nerves that weave through tumor tissue. The researchers report that a molecule best known for controlling the production of neurotransmitters in nerve cells—tyrosine hydroxylase, or TH—may help create a self-reinforcing communication loop between nerves and cancer cells. Their findings suggest that TH could serve both as a prognostic biomarker and as a potential therapeutic target.
The sympathetic nervous system is traditionally associated with the body’s “fight-or-flight” response. When activated, sympathetic adrenergic nerves release norepinephrine, a catecholamine that helps regulate heart rate, blood pressure, metabolism, and alertness. In cancer, however, these nerves can become part of the tumor microenvironment, the complex ecosystem of malignant cells, immune cells, blood vessels, connective tissue, and signaling molecules surrounding a tumor. Norepinephrine can bind to adrenergic receptors on cancer cells, particularly the β2-adrenergic receptor, and activate intracellular pathways that influence proliferation, survival, migration, and treatment response. Although previous studies had connected adrenergic signaling with breast cancer progression, the role of TH—the enzyme that initiates catecholamine synthesis—had not been sufficiently investigated in the interaction between sympathetic nerves and TNBC cells.
TH catalyzes the conversion of the amino acid tyrosine into L-DOPA, the first and rate-limiting step in the biosynthesis of dopamine, norepinephrine, and epinephrine. Because this reaction controls the rate at which catecholamines can be produced, TH is a critical determinant of adrenergic signaling. The new study examined TH expression in TNBC using online molecular databases and immunohistochemical analysis of clinical tumor samples. Immunohistochemistry uses antibodies to detect specific proteins in preserved tissue sections, allowing researchers to visualize where a molecule is expressed and compare its abundance across samples. The investigators found that TH expression was relatively high in TNBC tumor tissues and was closely associated with clinical staging and patient prognosis. This pattern raises the possibility that TH is not merely a marker of nerve presence but may reflect an active biological process linked to more aggressive disease.
To investigate how the relationship operates, the researchers established experimental systems in which TNBC cells were cocultured with PC12 cells. PC12 cells are derived from a rat pheochromocytoma and are widely used as a laboratory model of neuronal and neuroendocrine behavior because they can produce catecholamines and respond to neuronal growth signals. By labeling the two cell populations with fluorescent markers, the team could monitor their growth and interactions using an automated live-cell imaging platform called IncuCyte. The experiments showed that the presence of adrenergic nerve-like cells increased TNBC cell proliferation. The effect was linked to norepinephrine, indicating that the neurotransmitter released by the nerve model was not a passive byproduct but an active signal capable of stimulating malignant cell growth.
The consequences extended beyond proliferation. When TNBC cells were exposed to the adrenergic nerve model, they became less sensitive to chemotherapeutic agents. This phenomenon was assessed through drug-response experiments in coculture, where cancer-cell growth and survival were tracked over time. The results suggest that norepinephrine-mediated signaling can help tumor cells withstand the cellular stress imposed by chemotherapy. At the molecular level, the researchers examined proteins involved in DNA damage responses and apoptosis, the tightly regulated process of programmed cell death that many anticancer drugs attempt to trigger. Changes in these proteins were consistent with a cellular state in which chemotherapy-induced damage was less likely to culminate in apoptosis. In practical terms, the nerve-derived signal appeared to give TNBC cells a survival advantage precisely when treatment was intended to eliminate them.
The study then uncovered the other half of the interaction: TNBC cells could influence the nerve-like cells in return. The cancer cells secreted nerve growth factor, or NGF, a protein that supports neuronal development, survival, and remodeling. NGF is increasingly recognized as an important component of tumor–nerve communication. In the coculture system, exposure to TNBC cells increased TH expression in PC12 cells and enhanced norepinephrine production. The researchers measured these changes using several independent methods, including reverse-transcription quantitative PCR to quantify TH messenger RNA, immunofluorescence to visualize TH protein, and enzyme-linked immunosorbent assays to measure norepinephrine in the surrounding culture medium. Together, the findings indicate that TNBC cells can stimulate adrenergic cells to become more chemically active, effectively increasing the supply of norepinephrine available to the tumor.
This creates what the investigators describe as a positive feedback loop. Adrenergic nerve cells express TH, enabling them to synthesize norepinephrine. Norepinephrine then acts on TNBC cells to promote proliferation and reduce chemotherapy sensitivity. In response, TNBC cells release NGF, which increases TH expression in the nerve-like cells and boosts further norepinephrine production. The loop therefore links tumor growth with nerve activation: the more strongly the two cell populations communicate, the more favorable the environment may become for cancer-cell survival. The mechanism resembles a biological amplifier, in which an initial signal is repeatedly strengthened rather than dissipated. RNA sequencing performed before and after coculture supported the existence of broad transcriptional changes in both cell populations, suggesting that the interaction affects multiple pathways rather than a single isolated molecular event.
The most direct test of TH as a therapeutic target came from experiments that reduced TH expression or blocked its activity. When the researchers knocked down the TH gene, the nerve-like cells produced less norepinephrine. Pharmacological TH inhibitors produced a similar effect by interfering with the enzyme’s catalytic function. In both cases, the interventions weakened the ability of the adrenergic cells to stimulate TNBC proliferation and restored cancer-cell sensitivity to chemotherapy in the experimental models. These findings are important because they place TH upstream of the norepinephrine signal. Rather than blocking one of several receptors on the cancer cell, targeting TH could reduce catecholamine production at its source. The approach also provides a mechanistic explanation for why disruption of nerve–tumor communication might complement conventional anticancer treatment.
The results connect with a growing body of research showing that the nervous system is an active participant in cancer biology. Earlier studies have linked sympathetic signaling with breast cancer progression, bone metastasis, and responses to chemotherapy. Other work has suggested that β-adrenergic blockers, drugs commonly prescribed for cardiovascular conditions, may influence tumor behavior, although observational findings do not by themselves establish that these medicines can treat cancer. The current study focuses on a different point in the pathway: TH inside adrenergic nerve cells. It also complements earlier evidence that TNBC cells can produce NGF and respond to norepinephrine through β2-adrenergic receptors. By identifying a reciprocal NGF–TH–norepinephrine circuit, the researchers offer a more integrated view of how the tumor microenvironment may be remodeled by two-way communication.
Despite the promise, the findings remain preclinical. The central experiments relied on cell coculture models, including a PC12 neuronal system, rather than a complete human tumor containing intact nerves, immune cells, blood vessels, and stromal tissue. The study also did not establish whether TH inhibition can safely suppress tumor-associated adrenergic signaling in living patients. TH is essential for normal catecholamine production, so systemic inhibition could potentially affect cardiovascular function, movement, mood, attention, and other physiological processes. Any future treatment would need to determine whether cancer-selective delivery, carefully controlled dosing, or combination strategies could limit these risks. Further studies in animal models and well-characterized patient cohorts will be necessary to confirm whether TH expression predicts treatment response and whether inhibiting the enzyme improves outcomes without unacceptable toxicity.
Even with these limitations, the study shifts attention toward a promising therapeutic concept: treating cancer not only by attacking malignant cells directly, but also by disrupting the biological networks that sustain them. For TNBC, where the lack of established receptors restricts the number of targeted options, the adrenergic nerve–tumor axis could represent a new vulnerability. TH may help identify tumors that are particularly dependent on sympathetic signaling, while TH inhibitors or strategies that block NGF production and norepinephrine response could potentially be combined with chemotherapy. The research does not yet establish a ready-to-use cancer drug, but it reveals a molecular feedback circuit that may explain why some tumors grow faster and resist treatment in a nerve-rich environment. By placing tyrosine hydroxylase at the center of this conversation, the investigators provide a new framework for understanding—and potentially interrupting—the neural biology of triple-negative breast cancer.
Subject of Research: The interaction between sympathetic adrenergic nerves and triple-negative breast cancer cells, with a focus on tyrosine hydroxylase, norepinephrine, and chemotherapy resistance.
Article Title: Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions
Article References: Luo Y, Han Y, Nie H, et al. “Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions.” Journal of Molecular Medicine 104, article 53 (2026).
Image Credits: AI Generated
DOI: 10.1007/s00109-026-02657-x
Keywords: Tyrosine hydroxylase; norepinephrine; sympathetic adrenergic nerves; triple-negative breast cancer; chemotherapy sensitivity; nerve–tumor interaction; nerve growth factor; β2-adrenergic signaling; 3D mammosphere; cancer therapeutics
Tags: challenges in treating triple-negative breast cancerimpact of catecholamines on cancer cell signalingneurotransmitter regulation in cancer progressionnovel insights into nerve-cancerpotential therapeutic targeting of tyrosine hydroxylase in breast cancerpromoting tumor growth and metastasisrole of sympathetic adrenergic nerves in tumor microenvironmenttriple-negative breast cancer cellstumor-nerve crosstalk in aggressive breast cancerstyrosine hydroxylase as a prognostic biomarker in TNBC
